Skip to main content
ETON logo

ETON · Eton Pharmaceuticals, Inc.

Track ETON — free
$63.88 -0.05 (-0.08%) At close · Nov 16
Market Cap
$1.84B
Shares
28.84M
Volume · Nov 16 613.62K Avg daily vol (3M) 592.67K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$63.88 Open$64.29 Day$63.50–66.73 52W close$14.35–68.40 Avg vol 30d569K Short int2.0M · 6.9% of shares · 5.4d Short vol62% Last earningsNov 5, 2026 DataJan 2020–Nov 2026 Filing10-Q · Nov 5

Up next

Mar 18, 2027 Est · unconfirmed · in 17 wks

Latest documents

2026
Nov 5
Earnings call
Revenue rises 158%; full-year guidance raised above $175 million

Eaton Pharmaceuticals reported third-quarter revenue of $57.9 million, up 158%, and raised full-year 2026 guidance to more than $175 million from more than $145 million. Adjusted EBITDA reached $28.5 million, or 49% of revenue, and cash ended at $55.6 million.

6 source passages
Welcome to the Eaton Pharmaceuticals Third Quarter 2026 Earnings Conference Call. Third quarter revenue increased 158% to $57.9 million compared to $22.5 million in the third quarter of 2025. We are increasing our 2026 revenue guidance and now expect full-year revenue of more than $175 million. All from our previous guidance of more than $145 million. Adjusted EBITDA for the third quarter of 2026 was $28.5 million, or 49% of revenue, compared to $2.9 million, or 13% of revenue, in the prior year period. We ended the third quarter with $55.6 million in cash after making a $5 million prepayment on our debt facility during the quarter, which reduced outstanding principal balance to $22 million. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rises sharply as HEMANGEOL® acquisition drives growth

Eton Pharmaceuticals reported net revenues of $57,925, compared with $22,459, primarily driven by HEMANGEOL® and higher product sales. Operating cash flow was $49,901, compared with $22,075.

Revenue $57.93M ▲ 157.9% Net income $35.25M Diluted EPS $1.06
Read from the MD&A section
4 source passages
ETON PHARMACEUTICALS, INC. During the three months ended September 30, 2026, we had $57,925 in net revenues, compared to $22,459 during the three months ended September 30, 2025. The $35,466 increase was primarily driven by the acquisition of HEMANGEOL® in February 2026, and higher product sales, net of ALKINDI SPRINKLE®, KHINDIVI™, INCRELEX® product sales in the U.S., GALZIN®, DESMODA™ and Carglumic Acid. During the nine months ended September 30, 2026, net cash from operating activities was $49,901 compared to $22,075 during the nine months ended September 30, 2025. Open the document at this passage
Nov 5
Current report 8-K
Record quarterly revenue, raised full-year guidance

Eton Pharmaceuticals reported Q3 2026 revenue of $57.9 million, up 158%, and adjusted EBITDA of $28.5 million, or 49% of revenue. It raised 2026 revenue guidance to more than $175 million and expects at least a 40% adjusted EBITDA margin.

Financial results
4 source passages
Eton Pharmaceuticals Reports Third Quarter 2026 Financial Results Record Q3 2026 product sales of $57.9 million, 158% year-over-year growth; surpassed $200 million annualized revenue run rate goal five quarters ahead of schedule Q3 2026 fully diluted GAAP EPS of $1.06, non-GAAP fully diluted EPS of $0.50; EBITDA of $24.8 million, Adjusted EBITDA of $28.5 million or 49% of revenue The Company now expects 2026 revenue of more than $175 million, an increase from its previous guidance of more than $145 million. The Company also expects at least a 40% Adjusted EBITDA margin for 2026, up from its previous guidance of at least 35%. Open the document at this passage
Nov 5
Current report 8-K
ET-700 showed better tolerability but weaker copper inhibition

Eton Pharmaceuticals said ET-700 produced fewer treatment-related adverse events than GALZIN in a pilot study, while hepatic copper uptake fell 12% with ET-700 versus 46% with GALZIN; it plans additional study arms in 2027 for faster-release formulations.

Other events
3 source passages
Based on the median individual post-treatment-to-baseline uptake ratios, hepatic copper uptake decreased by 12% with ET-700 and 46% with GALZIN, compared with an 11% increase with placebo. Treatment-related adverse events occurred in 1 of 12 ET-700 participants compared with 8 of 12 GALZIN participants Company plans additional study arms in 2027 evaluating faster-release formulations to seek to improve copper absorption inhibition while preserving favorable safety profile Open the document at this passage
Nov 2
Current report 8-K
Other events

Eton Pharmaceuticals announced ET-900 to evaluate mecasermin for infantile and epileptic spasms, secured Baylor College of Medicine patent rights, and submitted a research IND for a Phase 2 study, targeting initial dosing in the first quarter of 2027.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$141.06M
Trailing 12 months
Net income (TTM)
$49.86M
Trailing 12 months
Revenue growth YoY
+157.9%
Year over year
Operating margin
28.8%
Trailing 12 months
P / E (TTM)
36.9
Trailing earnings · reciprocal yield 2.7%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$32.56M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+23.7%
Year over year · more shares
Price change (1Y)
+277.1%
Trailing year
Short interest
6.9%
Latest settlement · 5.4 days to cover
View all 125 metrics

AI Brief

Q2 FY26 earnings call · Aug 13, 2026
Q2 FY26

TL;DR. Eton Pharmaceuticals posted record Q2 revenue of $37.6 million (+99% YoY) with adjusted EBITDA margin reaching 43%, raised 2026 revenue guidance to exceed $145 million (from >$120M) and adjusted EBITDA margin guidance to at least 35% (from >30%), completed the Hemangeol relaunch and patient conversion ahead of schedule, and added late-stage candidate ASN-001 plus U.S. rights to Impavido.

Bullish
  • + Adjusted EBITDA margin expanded to 43% from 16% a year ago
  • + Raised full-year 2026 revenue guidance to exceed $145M from >$120M
  • + Raised full-year adjusted EBITDA margin guidance to at least 35% from >30%
Bearish
  • − Adjusted gross margin declined to 73% from 75% due to negative-margin ex-U.S. Increlex sales
  • − $3M ASN-001 upfront licensing payment will be expensed as R&D in Q3 2026, pressuring near-term R&D spend

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Neutral Fundamentals Excellent Quant / Vol Very High
Market backdrop VIX 19.3 · elevated Equity put/call 0.63
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +68%
above
Price vs 50-day avg +15%
above
RSI (14) 62
neutral
MACD trend Positive
52-week position 92%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +30%
trailing
6-month return +97%
trailing
YTD return +278%
this year
Relative strength +99%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $55 › 200d $38 — 50d above 200d
Institutional flow Accumulating
+17% holders QoQ · +66 funds added
Insider flow Distributing
Net -$16.5M over 90 days · 100% sells
Short interest Rising
6.89% of shares out · ▲ +2.2% MoM · 5.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
192 holders — near 3-yr high, broad support
Squeeze score 69
elevated · 0–100
Fundamentals
Excellent
Revenue growth +105%
Y/Y
Gross margin 53%
contracting
Free cash flow $10.2M
Balance sheet $4.6M
net debt
Quant / Vol
risk profile
Very High
Volatility 75%
annualized · 1-yr
Max drawdown −27%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Nov 5, 2026
2026
Revenue at least $175M
prior FY $79.95M midpoint +118.9% Y/Y
Adjusted EBITDA margin Non-GAAP at least 40%
full-year 2026
Adjusted gross margin Non-GAAP at least 70%
Previous outlook earlier release · from the Earnings Call filed Aug 13, 2026

Still-open targets the latest release did not restate under the same label.

Full year revenue · full year 2026 at least $145M
Adjusted EBITDA margin · full year 2026 at least 35%
Adjusted gross margin · full year 2026 at least 70%
R&D spending · full year 2026 $10M – $14M
Guided vs delivered · last 1 settled
2022 revenue 2022
guided at least $25M
$21.25M Miss −15.0%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+68% Bullish
Price vs 50-day avg
+15% Bullish
RSI (14)
62 Neutral
MACD trend
Positive Bullish
52-week position
92% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $55 › 200d $38 — 50d above 200d
Institutional flow Accumulating
+17% holders QoQ · +66 funds added
Insider flow Distributing
Net -$16.5M over 90 days · 100% sells
Short interest Rising
6.89% of shares out · ▲ +2.2% MoM · 5.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
192 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $14 Now $64 · 92% Range high $68
vs 200-day avg +68% vs 50-day avg +15%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Adjusted EBITDA non-GAAP $16.2M Q2 2026 —
GAAP → non-GAAP reconciliation
EBITDA $14.12M (the result of another reconciliation in this filing)
+$650K Inventory step-up expense (3)
+$1.47M Stock-based compensation (4)
+$0K Severance expense (5)
+$0K Acquisition/divestiture-related costs (6)
= Adjusted EBITDA $16.24M
EBITDA $14.1M the second quarter of 2026 —
GAAP → non-GAAP reconciliation
GAAP GAAP Net income (loss) $11.58M
+$22K Depreciation (1)
+$1.36M Intangible amortization expense (2)
+$1.01M Interest expense (including debt discount amortization and non-cash interest expenses)
+$140K Income tax expense
= EBITDA $14.12M
Non-GAAP earnings per share - Basic non-GAAP $0.69 the six months ended June 30, 2026 —
Non-GAAP earnings per share - Diluted non-GAAP $0.59 the six months ended June 30, 2026 —
Non-GAAP income per share - Basic non-GAAP $0.52 the three months ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP GAAP income (loss) per share - Basic $0.42
+$0.1 Non-GAAP adjustments
= Non-GAAP income per share - Basic $0.52
Non-GAAP income per share - Diluted non-GAAP $0.43 the three months ended June 30, 2026 filing —
GAAP → non-GAAP reconciliation
GAAP GAAP income (loss) per share - Diluted $0.35
+$0.08 Non-GAAP adjustments
= Non-GAAP income per share - Diluted $0.43
Non-GAAP Net income non-GAAP $14.3M the second quarter of 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ETON
Eton Pharmaceuticals, Inc.
this stock
$1.84B +277.8% +104.9% — 6.9%
TAK
Takeda Pharmaceutical Co Ltd
$68.98B +38.5% — — 0.1%
GALDY
Galderma Group AG
$53.03B +9.7% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
$49.67B +36.4% +4.3% 96.8 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
$40.66B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
192
% held
52.6%
Net QoQ
-4.8M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
144
View
Short & Settlement
Short Interest Rising
Shares short
2.0M
Days to cover
5.4d
Change
+42.8K sh
View
Short Volume
Short vol %
62%
As of
Nov 16, 2026
Short Total
View
Fails to Deliver
FTD shares
34
Value
$1.7K
As of
Oct 16, 2026
View
Off-Exchange
Off-exchange %
46.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$16.5M
Buyers / Sellers
0 / 5
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$80.0M
Net income (FY)
$-4.6M
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 5, 2026
This year
26

Eton Pharmaceuticals reported net revenues of $57,925, compared with $22,459, primarily driven by HEMANGEOL® and higher product sales. Operating cash flow was $49,901, compared with $22,075.

View
Proposed Sales
Value
$5.3M
Shares
80.6K
Filed
Nov 10, 2026
View
Exempt Offerings
Offering
$7.5M
Filed
Apr 8, 2020
View
Earnings & Events
Webcasts
Last webcast
Nov 5, 2026
View
Investor Relations
Latest news
Eton Pharmaceuticals Announces Li…
Published
Nov 2, 2026
View

Performance

5D 20D 120D MTD YTD
ETON -0.7% +29.8% +97.2% +22.4% +277.8%
SPY -1.7% -3.5% -1.4% -2.1% +8.5%
vs SPY +1.0% +33.2% +98.6% +24.5% +269.3%
Key facts CIK 1710340 CUSIP 29772L108 13F (30d) 183 filings 179 filers Visit website Investor relations